39,283
Views
0
CrossRef citations to date
0
Altmetric
Editorial

How Effective is Ketamine in the Management of Chronic Neuropathic Pain?

, , & ORCID Icon
Pages 517-519 | Received 05 Aug 2019, Accepted 12 Aug 2019, Published online: 15 Oct 2019

References

  • Colloca L , LudmanT , BouhassiraDet.al Neuropathic pain. Nat. Rev. Dis. Primers3(1), 17002 (2017).
  • Wieseler-Frank J , MaierSF , WatkinsLR. Central proinflammatory cytokines and pain enhancement. Neurosignals14(4), 166–174 (2005).
  • Morgan CJA , MuetzelfeldtL , CurranHV. Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study: the consequences of repeated ketamine use. Addiction105(1), 121–133 (2010).
  • Quibell R , PrommerEE , MihalyoM , TwycrossR , WilcockA. Ketamine*. J. Pain Symptom Manag.41(3), 640–649 (2011).
  • O’Brien SL , PangarkarS , PragerJ. The use of ketamine in neuropathic pain. Curr. Phys. Med. Rehabil. Rep.2(2), 128–145 (2014).
  • Zhang K , HashimotoK. An update on ketamine and its two enantiomers as rapid-acting antidepressants. Exp. Rev. Neurother.19(1), 83–92 (2019).
  • Peltoniemi MA , SaariTI , HagelbergNMet.al Rifampicin has a profound effect on the pharmacokinetics of oral S-ketamine and less on intravenous S-ketamine. Basic Clin. Pharmacol. Toxicol.111(5), 325–332 (2012).
  • Michelet D , BrasherC , HorlinA-Let.al Ketamine for chronic non-cancer pain: a meta-analysis and trial sequential analysis of randomized controlled trials. Eur. J. Pain22(4), 632–646 (2018).
  • SPRAVATO™ (esketamine) . Janssen Pharmaceutical (2018). www.spravato.com/
  • Aroni F , IacovidouN , DontasI , PourzitakiC , XanthosT. Pharmacological aspects and potential new clinical applications of ketamine: reevaluation of an old drug. J. Clin. Pharm.49(8), 957–964 (2009).
  • Wang X , DingX , TongYet.al Ketamine does not increase intracranial pressure compared with opioids: meta-analysis of randomized controlled trials. J. Anesth.28(6), 821–827 (2014).
  • Middela S , PearceI. Ketamine-induced vesicopathy: a literature review: ketamine and bladder. Int. J. Clin. Pract.65(1), 27–30 (2011).
  • Sigtermans MJ , van HiltenJJ , BauerMCRet.al Ketamine produces effective and long-term pain relief in patients with complex regional pain syndrome type 1. Pain145(3), 304–311 (2009).
  • Kiefer R-T , RohrP , PloppaAet.al Efficacy of ketamine in anesthetic dosage for the treatment of refractory complex regional pain syndrome: an open-label Phase II study. Pain Med.9(8), 1173–1201 (2008).
  • Eichenberger U , NeffF , SveticicGet.al Chronic phantom limb pain: the effects of calcitonin, ketamine, and their combination on pain and sensory thresholds. Anesth. Analg.106(4), 1265–1273 (2008).
  • Bosma RL , ChengJC , RogachovAet.al Brain dynamics and temporal summation of pain predicts neuropathic pain relief from ketamine infusion. Anesthesiology129(5), 1015–1024 (2018).
  • Huge V , LauchartM , MagerlWet.al Effects of low-dose intranasal (S)-ketamine in patients with neuropathic pain. Eur. J. Pain14(4), 387–394 (2010).
  • Lynch ME , ClarkAJ , SawynokJ , SullivanMJL. Topical 2% amitriptyline and 1% ketamine in neuropathic pain syndromes: a randomized, double-blind, placebo-controlled trial. Anesthesiology103(1), 140–146 (2005).
  • Rabi J , MinoriJ , AbadH , LeeR , GittlerM. Topical ketamine 10% for neuropathic pain in spinal cord injury patients: an open-label trial. Int. J. Pharm. Compd.20(6), 517–520 (2016).